Danielle Cohen1, Liesbeth M Hondelink2, Nienke Solleveld-Westerink2, Sandra M Uljee2, Dina Ruano2, Anne-Marie Cleton-Jansen2, Jan H von der Thüsen2, S Rajen S Ramai3, Pieter E Postmus3, Jacob F Graadt van Roggen4, Bart P C Hoppe5, Pieter C Clahsen6, Klaartje W Maas7, Els J M Ahsmann8, Alexandra Ten Heuvel9, Frank Smedts10, Ronald N van Rossem11, Tom van Wezel2. 1. Department of Pathology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands. Electronic address: d.cohen@lumc.nl. 2. Department of Pathology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands. 3. Department of Pulmonology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands. 4. Department of Pathology, Alrijne Hospital, Leiderdorp, The Netherlands. 5. Department of Pulmonology, Alrijne Hospital, Leiderdorp, The Netherlands. 6. Department of Pathology, Haaglanden Medical Centre (HMC), Den Haag, The Netherlands. 7. Department of Pulmonology, Haaglanden Medical Centre (HMC), Den Haag, The Netherlands. 8. Department of Pathology, Groene Hart Hospital (GHZ), Gouda, The Netherlands. 9. Department of Pulmonology, Groene Hart Hospital (GHZ), Gouda, The Netherlands. 10. Department of Pathology, Reinier de Graaf gasthuis (RdGG), Delft, The Netherlands. 11. Department of Pulmonology, Reinier de Graaf gasthuis (RdGG), Delft, The Netherlands.
Abstract
INTRODUCTION: Frequently, patients with locally advanced or metastatic NSCLC are screened for mutations and fusions. In most laboratories, molecular workup includes a multitude of tests: immunohistochemistry (ALK, ROS1, and programmed death-ligand 1 testing), DNA sequencing, in situ hybridization for fusion, and amplification detection. With the fast-emerging new drugs targeting specific fusions and exon-skipping events, this procedure harbors a growing risk of tissue exhaustion. METHODS: In this study, we evaluated the benefit of anchored, multiplexed, polymerase chain reaction-based targeted RNA sequencing (RNA next-generation sequencing [NGS]) in the identification of gene fusions and exon-skipping events in patients, in which no pathogenic driver mutation was found by DNA-based targeted cancer hotspot NGS (DNA NGS). We analyzed a cohort of stage IV NSCLC cases from both in-house and referral hospitals, consisting 38.5% cytology samples and 61.5% microdissected histology samples, mostly core needle biopsies. We compared molecular findings in a parallel workup (DNA NGS and RNA NGS, cohort 1, n = 198) with a sequential workup (DNA NGS followed by RNA NGS in selected cases, cohort 2, n = 192). We hypothesized the sequential workup to be the more efficient procedure. RESULTS: In both cohorts, a maximum of one oncogenic driver mutation was found per case. This is in concordance with large, whole-genome databases and suggests that it is safe to omit RNA NGS when a clear oncogenic driver is identified in DNA NGS. In addition, this reduced the number of necessary RNA NGS to only 53% of all cases. The tumors of never smokers, however, were enriched for fusions and exon-skipping events (32% versus 4% in former and current smokers, p = 0.00), and therefore benefited more often from the shorter median turnaround time of the parallel approach (15 d versus only 9 d in the parallel workup). CONCLUSIONS: We conclude that sequentially combining DNA NGS and RNA NGS is the most efficient strategy for mutation and fusion detection in smoking-associated NSCLC, whereas for never smokers we recommend a parallel approach. This approach was shown to be feasible on small tissue samples including for cytology tests, can drastically reduce the complexity and cost of molecular workup, and also provides flexibility in the constantly evolving landscape of actionable targets in NSCLC.
INTRODUCTION: Frequently, patients with locally advanced or metastatic NSCLC are screened for mutations and fusions. In most laboratories, molecular workup includes a multitude of tests: immunohistochemistry (ALK, ROS1, and programmed death-ligand 1 testing), DNA sequencing, in situ hybridization for fusion, and amplification detection. With the fast-emerging new drugs targeting specific fusions and exon-skipping events, this procedure harbors a growing risk of tissue exhaustion. METHODS: In this study, we evaluated the benefit of anchored, multiplexed, polymerase chain reaction-based targeted RNA sequencing (RNA next-generation sequencing [NGS]) in the identification of gene fusions and exon-skipping events in patients, in which no pathogenic driver mutation was found by DNA-based targeted cancer hotspot NGS (DNA NGS). We analyzed a cohort of stage IV NSCLC cases from both in-house and referral hospitals, consisting 38.5% cytology samples and 61.5% microdissected histology samples, mostly core needle biopsies. We compared molecular findings in a parallel workup (DNA NGS and RNA NGS, cohort 1, n = 198) with a sequential workup (DNA NGS followed by RNA NGS in selected cases, cohort 2, n = 192). We hypothesized the sequential workup to be the more efficient procedure. RESULTS: In both cohorts, a maximum of one oncogenic driver mutation was found per case. This is in concordance with large, whole-genome databases and suggests that it is safe to omit RNA NGS when a clear oncogenic driver is identified in DNA NGS. In addition, this reduced the number of necessary RNA NGS to only 53% of all cases. The tumors of never smokers, however, were enriched for fusions and exon-skipping events (32% versus 4% in former and current smokers, p = 0.00), and therefore benefited more often from the shorter median turnaround time of the parallel approach (15 d versus only 9 d in the parallel workup). CONCLUSIONS: We conclude that sequentially combining DNA NGS and RNA NGS is the most efficient strategy for mutation and fusion detection in smoking-associated NSCLC, whereas for never smokers we recommend a parallel approach. This approach was shown to be feasible on small tissue samples including for cytology tests, can drastically reduce the complexity and cost of molecular workup, and also provides flexibility in the constantly evolving landscape of actionable targets in NSCLC.
Authors: Soo-Ryum Yang; Umut Aypar; Ezra Y Rosen; Douglas A Mata; Ryma Benayed; Kerry Mullaney; Gowtham Jayakumaran; Yanming Zhang; Denise Frosina; Alexander Drilon; Marc Ladanyi; Achim A Jungbluth; Natasha Rekhtman; Jaclyn F Hechtman Journal: Clin Cancer Res Date: 2020-12-03 Impact factor: 12.531
Authors: Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat Journal: Blood Adv Date: 2021-10-12
Authors: Liesbeth M Hondelink; Melek Hüyük; Pieter E Postmus; Vincent T H B M Smit; Sami Blom; Jan H von der Thüsen; Danielle Cohen Journal: Histopathology Date: 2021-11-16 Impact factor: 7.778
Authors: Lázaro Antonio Campanha Novaes; Luciane Sussuchi da Silva; Pedro De Marchi; Rodrigo de Oliveira Cavagna; Flavia Escremim de Paula; Maicon Fernando Zanon; Adriane Feijó Evangelista; Eduardo Caetano Albino da Silva; Vinícius Duval da Silva; Letícia Ferro Leal; Rui Manuel Reis Journal: Transl Lung Cancer Res Date: 2021-01
Authors: Martin Zacharias; Gudrun Absenger; Karl Kashofer; Robert Wurm; Jörg Lindenmann; Angelika Terbuch; Selma Konjic; Stefan Sauer; Franz Gollowitsch; Gregor Gorkiewicz; Luka Brcic Journal: Transl Lung Cancer Res Date: 2021-11